Flipside Finance
PF

Pfizer Inc.

PFEEquity
$25.01+0.40%
24h Volume: $0.03B

AI Summary

Updated 8h ago

Pfizer Inc

Pfizer Inc. (PFE) is in a mixed position. Some indicators are above average, others below, but nothing is at an extreme that demands attention. For reference: Flow Score 56/100, Trend & Momentum Score 48/100.

61Above average
Market position

Market Positioning

39Below avg
Extension
74Above avg
Momentum
71Above avg
Flow
29Below avg
Volatility

What's Happening

Updated 48d ago

Pfizer locks in 2026 guidance and cost-reset targets

On 2026-05-29, Pfizer reaffirmed full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and EPS guidance of $2.80 to $3.00, while also calling for operational revenue growth of about 4% at the midpoint excluding COVID-19 and LOE products. The detail that matters is the margin bridge — Pfizer is pairing top-line stabilization with $23.0 billion to $25.0 billion in combined adjusted SI&A and R&D spending, which signals the company is still leaning hard on its cost realignment program to defend earnings power.

The Bigger Picture

Updated 6d ago
Macro context will be updated shortly
Flow Score: 37/100Trend Score: 41/1003-Month Return: -8.0%

Upcoming Catalysts

Updated 48d ago
Late July 2026Pre-earnings investor updates

Pfizer often uses the weeks before earnings to reinforce guidance and shape expectations through investor communications and conference appearances. Any update that clarifies the pace of operational revenue growth or expense control could matter more than the headline itself. [6][4]

Aug 4Q2 2026 earnings

Pfizer is widely expected to report around this date based on market calendars. Investors will focus on whether the company keeps validating its 2026 revenue and EPS guide and whether cost realignment is continuing to support margins. [3][1]

Next 90 daysFollow-through on 2026 guidance

Investors will watch for any management commentary that confirms the full-year revenue range of $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3.00. The key issue is whether Pfizer can hold that frame without further reliance on one-off support from legacy product trends. [1]

Positive Catalyst
Earnings

Technical Analysis

Market Positioning

Where does this asset sit across four dimensions? Extension (how stretched price is vs its own history), Momentum (RSI, MACD, rate of change), Flow (volume and money flow), and Volatility (how quiet or active). Each bar shows a 0–100 percentile compared to the last year of data. Key levels show the nearest demand and supply zones from our confluence analysis.

Extension
[avg: 39th]
39thpercentile
Low
Normal
High
39th percentile
Momentum
[avg: 74th]
74thpercentile
Low
Normal
High
74th percentile
Flow
[avg: 71st]
71stpercentile
Low
Normal
High
71st percentile
Volatility
[avg: 29th]
29thpercentile
Low
Normal
High
29th percentile

Key Levels

Demand: $23–$25 (2.8% below)
score: 11.50
Supply: $26–$28 (6.6% above)
score: 13.50
View full Key Levels section →

Looking at the full picture for Pfizer Inc. (PFE): extension is slightly below average (39th percentile), momentum is above average (74th percentile), flow is above average (71st percentile), volatility is below average (29th percentile).

Conclusion

Pfizer Inc. (PFE) is in a mixed position. Some indicators are above average, others below, but nothing is at an extreme level that defines the current setup strongly in either direction. There is not a strong signal here in either direction. This is an asset to watch rather than act on right now. These readings update daily. Flipside shows what is happening now, grounded in the data — not what will happen next.

Your portfolio. Your context. Smarter decisions.

Connect your holdings and let the Flipside Agent analyze market changes through the lens of your portfolio.

AI + Portfolio

Personalized insights based on your actual holdings

Daily Briefing

Major market movements delivered to your inbox

Watchlists

Track the assets that matter most to you

Create your free account

No credit card required